Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to $9.3 million.

  • Sunshine Biopharma's Cash & Equivalents fell 2375.93% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 2375.93%. This contributed to the annual value of $9.7 million for FY2024, which is 4054.55% down from last year.
  • Per Sunshine Biopharma's latest filing, its Cash & Equivalents stood at $9.3 million for Q3 2025, which was down 2375.93% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Cash & Equivalents ranged from a high of $41.7 million in Q2 2022 and a low of $1.7 million during Q2 2021
  • Over the past 5 years, Sunshine Biopharma's median Cash & Equivalents value was $12.2 million (recorded in 2024), while the average stood at $14.6 million.
  • As far as peak fluctuations go, Sunshine Biopharma's Cash & Equivalents surged by 1652283.49% in 2021, and later crashed by 5353.05% in 2023.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Cash & Equivalents stood at $2.0 million in 2021, then soared by 967.22% to $21.8 million in 2022, then decreased by 25.35% to $16.3 million in 2023, then tumbled by 40.55% to $9.7 million in 2024, then fell by 3.92% to $9.3 million in 2025.
  • Its Cash & Equivalents stands at $9.3 million for Q3 2025, versus $10.3 million for Q2 2025 and $8.1 million for Q1 2025.